1
/
of
0
FDA Humacyte BLA Review and Approval Correspondence for ATEV Product
FDA Humacyte BLA Review and Approval Correspondence for ATEV Product
Regular price
$69.00 USD
Regular price
Sale price
$69.00 USD
Unit price
/
per
Original Request: FDA communications with Humacyte, Inc. regarding review and approval/rejection of Humacyte’s Biologics License Application for their ATEV (Acellular Tissue-Engineered Vessel) product used for vascular trauma.
Tags: Pharma, EIR, 2024
Tags: Pharma, EIR, 2024
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details